Activation of Biobank Registry for Bilio-pancreatic Diseases
BIO-PANCREAS
Activation of Biobank for Association Study Between Environmental and Genetic Factors in Inflammatory, Functional and Neoplastic Bilio-pancreatic Diseases
1 other identifier
observational
2,000
1 country
1
Brief Summary
The purpose of establishing the biobank is to create a collection of biological material and clinical data, with a prospective and retrospective mold, in order to investigate the role of genetic predisposition in multifactorial bilio-pancreatic diseases, so that an evaluation of the possible association in the pathogenesis of exogenous factors with endogenous factors can be allowed. Multifactorial diseases are in fact an expression of genetic predisposition upon which one or more environmental stimuli act. Usually the aforementioned factors are not capable individually of triggering disease but, when simultaneously present, can cause the pathological phenotype. Therefore, it becomes important in the description of disease pathogenesis to identify as many risk factors for disease prevention and early diagnosis.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jun 2021
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
June 9, 2021
CompletedFirst Submitted
Initial submission to the registry
August 8, 2024
CompletedFirst Posted
Study publicly available on registry
August 13, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2027
ExpectedStudy Completion
Last participant's last visit for all outcomes
December 31, 2030
May 2, 2025
April 1, 2025
6.6 years
August 8, 2024
April 30, 2025
Conditions
Outcome Measures
Primary Outcomes (1)
The rate of patients with each pancreatic disorder presenting with certain exposures or certain biomarkers
The rate of patients with each pancreatic disorder presenting with certain exposures or certain biomarkers will be evaluated by descriptive statistics and when available compared with that of subjects without such disorders (controls).
Tthrough study completion, an average of 1 year
Eligibility Criteria
Patients with biliopancreatic disorders
You may qualify if:
- age \>= 18 years
- signed informed consent
You may not qualify if:
- age \< 18 years
- unwilling to sign informed consent
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
IRCCS OSpedale San Raffaele
Milan, 20132, Italy
Biospecimen
* peripheral blood; * portal blood; * saliva; * urine; * stool; * cystic fluid; * pancreatic juice; * biopsy tissue;
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Paolo Giorgio Arcidiacono, MD
IRCCS Ospedale San Raffaele
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor
Study Record Dates
First Submitted
August 8, 2024
First Posted
August 13, 2024
Study Start
June 9, 2021
Primary Completion (Estimated)
December 31, 2027
Study Completion (Estimated)
December 31, 2030
Last Updated
May 2, 2025
Record last verified: 2025-04